EMDN for the same device; that is normal. What matters is that the intended use, technological characteristics, and risk profile match the Japanese term’s definition. Teams that treat JMDN as a one-time lookup routinely hit review delays; teams that treat it as a design input for classification, labeling, and vigilance move faster and with fewer queries.

Anatomy of a JMDN Term: Hierarchy, Definitions, and How It Differs from GMDN/EMDN

A JMDN entry typically combines a code, a generic device name, and an official Japanese definition that centers on intended purpose, principal mechanism, and sometimes patient contact or use context. Many terms include notes that exclude borderline technologies or redirect to a more specific code. While GMDN/EMDN also group by intended use, JMDN is tailored to Japan’s regulatory pathways: certain codes map more predictably to Ninsho certification lists, while others historically correlate with Shonin review. Do not assume one-to-one crosswalks; the same endoscope, syringe, or orthopedic plate can live under different generic constructs depending on how the term is defined in Japanese.

JMDN hierarchy matters for families and variants. Where you claim a device “family,” ensure each variant’s intended use and technology stay within the JMDN definition’s bounds. If a software option adds diagnostic functionality that shifts the intended purpose, you may need a different code or a separate listing. For IVDs, JMDN terms often distinguish analyte-specific assays from platform reagents/instruments. For combination products, JMDN focuses on the device constituent’s role; drug claims live elsewhere in the dossier. Create a traceability table that ties your intended use, key features, and risk controls to the precise sentences in the JMDN definition—reviewers should be able to verify fit in two clicks.

How to Select the Correct JMDN: A Practical, Reproducible Workflow

Successful teams use a five-step routine to avoid misclassification:

• 1) Lock the intended purpose: Author a crisp, Japan-operable intended use statement (who, what, where, outcome). Remove marketing adjectives; keep clinical verbs. This text becomes your compass against candidate terms.
• 2) Fix the principal mechanism: Identify the core technology (e.g., mechanical support, optical visualization, electrical stimulation, immunoassay chemistry). If multiple mechanisms exist, rank by clinical effect hierarchy.
• 3) Screen candidate JMDN terms: Pull a long list by keywords (Japanese and English), then eliminate terms whose definition conflicts with your intended use or mechanism. For borderline fits, note the exclusion language.
• 4) Run comparators and predicates: Identify marketed Japanese devices with similar intended use/tech. If their JMDN codes differ, analyze why (legacy term, narrower scope, software add-ons). Document your reasoning.
• 5) Record the decision trail: Create a one-page rationale (intended use → mechanism → chosen JMDN → alternatives considered → why rejected). Store under change control; you will need it for queries and future variants.

Apply the same method to SaMD, where intended use often hinges on information outputs and clinical decision support. If your software crosses from data handling to diagnostic inference, the correct JMDN may move from “accessory/tool” to a “diagnostic” term with very different submission and vigilance implications. For kits and procedure packs, check whether JMDN expects a set term or whether each component requires its own code. The goal is consistency: the JMDN must tell the same story as your labeling, risk management file, and clinical evidence.

What JMDN Triggers for Submissions: Todokede, Ninsho, Shonin, and Dossier Impacts

Once a JMDN is selected, it often implies the most likely route—notification for low-risk, certification for standardized Class II lists, or approval for higher-risk or novel technologies. While the legal basis is broader than nomenclature alone, JMDN sits at the center of how reviewers and Registered Certification Bodies frame your product. Align the code early with your submission plan and build artifacts that flow from it:

• Classification memorandum: JMDN code, risk class rationale, comparator devices, and any clinical standard references that support route selection.
• Labeling and IFU draft: Wording must reflect the intended use that anchors your JMDN; discrepancies are red flags during validation.
• Clinical evidence path: For approval routes, your clinical evaluation or study plan should map to the risks inherent in the JMDN term (diagnostic accuracy endpoints for IVDs; safety/performance for implants; human factors for use-critical tools).
• QMS scope: Manufacturing sites, processes, and suppliers tied to the JMDN-defined device (and variants) should appear consistently in your quality documentation and audit plans.

During review, integrated queries frequently test whether your control strategy matches the generic definition. For example, if the JMDN emphasizes patient contact and sterility, expect deeper probes of biocompatibility, sterilization validation, and packaging integrity. If it emphasizes measurement accuracy, expect method validation, calibration, and traceability questions. Keep a “decision map” at the front of your file routing reviewers from JMDN rationale → intended use → key evidence leaves. This reduces clock-stops and shows your team understands how nomenclature drives risk and proof.

Software as a Medical Device (SaMD): JMDN Coding, IMDRF Concepts, and Update Strategy

For SaMD, JMDN selection hinges on what clinical decision the software supports or drives. A device that visualizes and stores images may sit under a tool/utility term; one that analyzes images to flag suspected disease will fall under a diagnostic term with higher evidentiary expectations. Align your JMDN with recognized SaMD definitions and risk categorization frameworks (see IMDRF’s work on SaMD; reference high-level concepts from the International Medical Device Regulators Forum to keep terminology consistent). Then reflect the term in your clinical evaluation plan: performance metrics (sensitivity/specificity), dataset representativeness for Japanese practice, and update procedures for algorithms.

Plan for updates. If your JMDN implies diagnostic function, incremental software changes that alter intended use or performance claims can trigger prior review rather than simple notification. Maintain a change matrix that maps software version changes to impact on intended use, risk controls, cybersecurity posture, and labeling; classify each change against Japan’s reporting categories. For AI/ML features, pre-specify data governance, drift monitoring, and re-training controls; if the product pattern-matches into a JMDN that expects stable performance claims, uncontrolled model evolution will attract queries. Align your UDI/label updates with the same logic so that database records don’t drift from JMDN-anchored claims.

IVDs, Consumables, and Kits: JMDN Nuances that Affect Evidence and Labeling

IVDs require special attention because JMDN often separates assays by analyte/use from platform reagents/instruments. An HbA1c assay will not share a code with a general photometer even if they are used together. Evidence must follow the term: accuracy/precision studies, LoD/LoQ, traceability to reference methods, and matrix effects for assay terms; calibration, linearity, and carryover for instruments. If you bundle items, check whether JMDN provides a kit/set term; otherwise, label components individually and maintain cross-references so procurement and vigilance remain unambiguous.

For consumables (syringes, tubing, surgical disposables), JMDN often points to materials and contact categories. That has downstream effects: biocompatibility endpoints (cytotoxicity, sensitization, irritation), sterilization validation scope, and shelf-life testing are shaped by the term’s definition. Human factors also follow the code—JMDN terms that imply self-administration or use in non-clinical settings raise usability and labeling expectations specific to Japanese patients and caregivers. Keep Japanese-language IFUs aligned to the term, and build a vigilance plan that uses the same generic concepts to code adverse events consistently.

UDI, Databases, and Post-Market Vigilance: Keeping JMDN, Labels, and Listings in Sync

Japan’s unique device identification and product listing processes rely on consistent generic naming. A change in JMDN—or a shift in intended use that should trigger a new JMDN—reverberates through UDI records, distributor catalogs, hospital ordering systems, and vigilance databases. Treat JMDN as a master data element: when it changes, your systems must propagate updates to labels, IFUs, UDI data, and safety coding. Misalignment is a common source of inspection findings because it signals that the “floor” (marketed packs, database entries) no longer matches the “file” (dossier claims).

Operationalize vigilance around the generic term. Your complaint coding, trend analysis, and field safety notices should reference the same JMDN concept to enable meaningful aggregation and signal detection. If you manage a family across multiple codes (e.g., accessories with a different JMDN), maintain cross-family analytics so that patterns aren’t missed. Finally, ensure your distributor agreements require prompt reflection of JMDN-anchored label changes in all downstream systems; Japan places legal responsibility on the authorization holder, so you must be able to prove that field data reflect the current generic definition.

Governance, Crosswalks, and Best Practices for Global Portfolios

Build a nomenclature governance process that treats JMDN as a controlled master data field, just like part numbers and SKUs. Practical elements include: a single-owner glossary; bilingual intended-use templates; a crosswalk repository between JMDN, GMDN, and EMDN; and a change-control SOP that flags when intended-use drift or technological updates warrant re-coding. For companies that centralize naming in global PLM/ERP, create a Japan overlay that enforces JMDN fidelity before submissions proceed. Train regulatory, labeling, quality, vigilance, and commercial teams on how the Japanese term drives route, evidence, and market operations.

Common pitfalls include over-broad families (variants exceed the JMDN definition), predicate bias (copying a competitor’s code without reading the Japanese definition), and label drift (marketing language adds claims that move the intended use beyond the term). The antidote is boring but effective: a standing monthly review of code selections and any new claims, a short rationale for every decision, and a pre-submission identity check that reconciles JMDN with Module 1/labels/UDI. When in doubt on borderline cases or novel tech, seek scientific dialogue with the agency; a brief alignment early prevents months of rework later with the PMDA.